{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:22:38Z","timestamp":1773832958102,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) -T cell therapy has entered the breakthrough era, characterized by a blend of therapeutic opportunities and challenges. With the integration of genome-editing technology, CAR-T cells will be empowered to become super warriors in eradicating tumor cells and attacking various tumors, including T-cell malignancies and acute myeloid leukemia. Notably, the optimization of CAR-T cells, including efficacy, safety, and manufacturing speed, coupled with other therapeutic strategies such as radiotherapy, hematopoietic stem cell transplantation, small-molecule inhibitors, and bispecific antibodies, could revolutionize the therapeutic landscape of tumors. Consequently, next-generation cellular immunotherapy, including universal CAR-NK cells and synergistic combination approaches, are anticipated to significantly impact cancer treatment in the coming decade. Nevertheless, the failure rates of CAR-T therapy continue to be significant. The challenge lies in determining the optimal combination strategy and identifying reliable and robust biomarkers to effectively select the patients who will derive the greatest benefit from CAR-T therapy. Herein, we highlight recent innovations in CAR-T products, combination strategies and predictive biomarkers of response presented at the 2023 ASH Annual Meeting.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1389324","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T05:17:21Z","timestamp":1712726241000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference"],"prefix":"10.3389","volume":"15","author":[{"given":"Tingting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1182\/blood-2023-179868","article-title":"Five year outcomes of patients with large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel: results from the US lymphoma CAR-T cell consortium","volume":"142","author":"Spiegel","year":"2023","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1182\/blood-2023-182565","article-title":"Ablation of cullin-5 in primary human T cells improves tumor killing and persistence in BCMA-targeting CAR-T cells in a multiple myeloma model","volume":"142","author":"Bachl","year":"2023","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood-2023-190073","article-title":"Engineered natural killer cells expressing chimeric ilt receptors (CIR) effectively target HLA-G positive AML tumor cells","volume":"142","author":"Duong","year":"2023","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2023-181087","article-title":"An \u201cOff-the-shelf\u201d CD2 universal CAR-T therapy combined with a long-acting IL-7 for T-cell Malignancies","volume":"142","author":"Xiang","year":"2023","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1093339","article-title":"Editorial: The mechanism and novel strategies of overcoming resistance of hematological Malignancies to CAR-T cell killing","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12943-023-01775-1","article-title":"CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks","volume":"22","author":"Hovhannisyan","year":"2023","journal-title":"Mol Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1182\/blood-2023-185216","article-title":"Low dose total body irradiation improves CD19 CAR-T expansion, persistence, and trafficking, leading to enhanced efficacy in large B-cell lymphoma","volume":"142","author":"Alhomoud","year":"2023","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2023-185697","article-title":"Neither conditioning chemotherapy nor gvHD-prophylaxis: CD7 CAR-T treatment bridging to haplo-HSCT","volume":"142","author":"Hu","year":"2023","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2023-186225","article-title":"Dasatinib and CAR-T cell therapy for newly diagnosed ph-positive acute lymphoblastic leukemia in adults","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2023-177703","article-title":"Glofitamab monotherapy in patients with non-hodgkin B-cell lymphoma after failing CAR T-cell infusion: primary analysis of the bicar study, a phase II lysa study","volume":"142","author":"Sesques","year":"2023","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood-2023-174209","article-title":"Mosunetuzumab plus polatuzumab vedotin demonstrates a favorable safety profile and efficacy in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): primary analysis of a phase ib\/II study","volume":"142","author":"Budde","year":"2023","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2023-187371","article-title":"Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma","volume":"142","author":"Merz","year":"2023","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1182\/blood-2023-180819","article-title":"Baseline immune state and T cell clonal kinetics are associated with response to CAR-T therapy in large B-cell lymphoma","volume":"142","author":"Maurer","year":"2023","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood-2023-173798","article-title":"An inflammatory biomarker signature reproducibly predicts CAR-T treatment failure in patients with aggressive lymphoma across the zuma trials cohorts","volume":"142","author":"Raj","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1389324\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T05:17:24Z","timestamp":1712726244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1389324\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2024.1389324"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1389324","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"article-number":"1389324"}}